|Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the
| ||Audit Committee Charter||Compensation Committee Charter||Nominating and Corporate Governance Committee Charter|
|Sol Barer, Ph.D. |
|Sol Barer, Ph.D.|
Board Chairman, Chair of Compensation Committee
Dr. Sol Barer has served on the Edge Therapeutics, Inc. Board of Directors since September of 2011 and is the current Board Chairman and Chair of Compensation Committee. He is the Managing Partner of SJ Barer Consulting and was the founder of the group at Celanese that spun out to form Celgene Corporation. Dr. Barer has spent 18 years leading the company as President, COO and CEO, culminating with his tenure as Celgene’s Executive Chairman and Chairman before retiring in June of 2011. Under h...
|Isaac Blech |
Board Vice Chairman
Isaac Blech has served as the Vice Chairman of Edge Therapeutics, Inc. since January of 2013. His current roles include Founder and Vice Chairman of Cerecor, Inc., a private company developing new treatments for central nervous system disorders and Director of ContraFect Corporation, a private company developing therapies for infectious diseases. Since 2011, he has served as Vice Chairman of Premier Alliance Group, a public company working in the areas of financial regulations, clean energy a...
| || ||
|Rosemary A. Crane || || ||
|Steve Glover ||
|James J. Loughlin
|James J. Loughlin|
Chair of Audit Committee
Mr. Loughlin has served on the Board of Directors at Edge Therapeutics Inc. since November of 2011 and is the current Chair of the Audit Committee. Since 2007, he has served as an independent director for Celgene Corporation, where he has chaired the Audit Committee. Mr. Loughlin has also been a member of Celgene’s Compensation Committee since 2008. He is a member of the Board of InspireMD, served as a member of the Board and lead director of Datascope Corporation and on the Board of Alfacell...
|| || |
|Liam Ratcliffe, M.D., Ph.D. |
|Liam Ratcliffe, M.D., Ph.D.|
Liam Ratcliffe joined the Edge Board of Directors in 2016. Liam is a Managing Director at New Leaf Venture Partners, and concentrates on biopharmaceutical investing. Liam joined New Leaf in September 2008. Liam was previously Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Mid West region (based in Ann A...
Print Page Email Page RSS Feeds Email Alerts IR Contacts